Convergence of Innovation, Angels in MedCity Workshop
Newable Private Investing, in conjunction MedCity, would like to invite you to attend our first investor workshop of 2018.
This workshop will explore the convergence of innovations that have disrupted life sciences. We have recently seen a rapid proliferation of fast moving innovations that have disrupted traditional industries, examples such as the use of Artificial Intelligence within precision medicine and patient stratification spring to mind, but in reality the convergence of information technology and life sciences have created fast evolving and exciting industry verticals.
Platforms such as IBM Watson and Babylon Health underpin this proliferation, and one as an investor must not only understand the potential opportunities, but also the risks associated with the creation of new industries.
17:45 — Registration
18:00 — Welcome from Sarah Haywood, CEO at MedCity
18:05 — Welcome from Anthony Clarke, Managing Director at NPI
18:20 — The Innovation Cycle and Implications for Healthcare, Hitesh Thakrar, Partner at Syncona
18:35 — Investment Opportunities within New Industry Verticles, Simon Kerry, Operating Partner at ALS LLP
18:50 — Founders Story, Scaling a Healthcare Businesss , – Anthony Finbow, Eagle Genomics
19:05 — Fostering Innovations, – Chris Molloy, Medicines Discovery Catapult
19:15 — Patent Blackspots, Ruth Wright/Fiona Stevens, Gill Jennings & Every
19:30 — Next steps
19:35 — Networking
Please note: this is an event targeted at a specialist audience. We reserve the right to reject requests to attend from people not directly invited by the organisers.
Hitesh Thakrar – Partner – Syncona and NPI
Hitesh Thakrar has extensive experience with investing in innovation businesses having managed the £1bn ADIA Innovation Fund and currently being a Partner at Syncona, the £1bn life sciences Fund. Hitesh also sits on the board of the Alan Turing Institute, which has a strong focus on Artificial Intelligence related research, so he is well placed to discuss the possible implications of converging innovations within life sciences.